Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma Meeting Abstract
| Authors: | Wolchok, J. D.; Thomas, L.; Bondarenko, I. N.; O'Day, S.; Weber, J. S.; Garbe, C.; Francis, S.; Ibrahim, R. A.; Hoos, A.; Robert, C. |
| Abstract Title: | Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma |
| Meeting Title: | 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 29 |
| Issue: | 18 Suppl. |
| Meeting Dates: | 2011 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2011-06-20 |
| Language: | English |
| ACCESSION: | WOS:000208865800021 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2011.29.18_suppl.lba5 |
| Notes: | Meeting Abstract: LBA5 -- Source: Wos |
